# Glulisine + Lantus in Type I Patients

> **NCT00545337** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 60 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insuline glulisine

## Key facts

- **NCT ID:** NCT00545337
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2009-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545337, "Glulisine + Lantus in Type I Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00545337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*